4 articles
AbbVie's dual IL-1α/IL-1β antibody beat placebo on HiSCR75 in the 1,400-patient INTREPID trial, with an 8-point gap that is smaller than phase 2 suggested.
Lilly's triple agonist has won four phase 3 trials and is due for US filing in early 2027. Until then, anything sold online as retatrutide is unapproved and of unknown quality.
Eplontersen missed its primary endpoint in 1,432 patients with amyloid cardiomyopathy, yet slowed functional decline. The explanation lies in what patients were already taking.
The phase 3 trial, published in NEJM, nearly doubled progression-free survival in ESR1-mutated ER-positive breast cancer. Overall survival remains immature, and two FDA decisions are due by December.
